AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-61727 |   Healthcare

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Autoimmune Disorder Drug Delivery Devices Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET

7.1 GLOBAL AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA AUTOIMMUNE DISORDER DRUG DELIVERY DEVICES MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Amgen Inc.

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 AbbVie Inc.

16.3 Bayer AG

16.4 Biogen Inc.

16.5 Bristol-Myers Squibb Company

16.6 Eli Lilly & Company

16.7 F. Hoffmann-La Roche Ltd

16.8 GlaxoSmithKline plc  

16.9 Johnson & Johnson Services, Inc.

16.10 Merck KGaA

16.11 Novartis AG

16.12 Sanofi S.A.

16.13 Teva Pharmaceutical Industries Ltd.

16.14 UCB Pharma SA.

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Product Type
Pen Injectors
Auto-Injectors
Pre-filled Syringes
Vials
By Manufacturing Type
In-House Manufacturing
Outsourced Manufacturing
By Indication
Rheumatoid Arthritis
Psoriasis
Multiple Sclerosis
Inflammatory Bowel Diseases
Systemic Lupus Erythematosus

Companies

Amgen Inc.
AbbVie Inc.
Bayer AG
Biogen Inc.
Bristol-Myers Squibb Company
Eli Lilly & Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc  
Johnson & Johnson Services, Inc.
Merck KGaA
Novartis AG
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
UCB Pharma SA.

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.